Mirati Therapeutics, Inc.
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinic…
Biotechnology
US, San Diego [HQ]
MRTX/Financials
Segments · Problems · Premarket · Compliance
Segment Analysis
Segments · Problems · Premarket · ComplianceSegment Analysis
Revenue · By Business Segment
These hierarchically ordered segment trees are sourced from the most recent 10-K filings, directly from the SEC.
Not available for MRTX
Revenue · By Area
This map and table comes from the most recent 10-K filings, directly from the SEC.
Not available for MRTX